Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nexus NeuroTech Ventures is a venture capital firm founded in 2023 and headquartered in San Francisco, California. The firm is dedicated to advancing technologies that address brain disorders, including neurodegenerative, neuropsychiatric, and neurodevelopmental conditions. These include significant health issues such as Parkinson’s disease, bipolar disorder, and autism spectrum disorder. Nexus NeuroTech Ventures aims to support solutions that enhance the diagnosis, treatment, and management of these complex conditions.
As a newly established firm, Nexus NeuroTech Ventures is in the early stages of building its portfolio and operational framework. The firm focuses on investments in North America and is actively seeking innovative companies that align with its mission. Although specific metrics such as assets under management (AUM) have not been disclosed, the firm is committed to fostering advancements in brain health technologies through its investment strategies and support programs.
Nexus NeuroTech Ventures invests in a diverse range of technologies and services aimed at addressing brain disorders. Their investment strategy encompasses several key areas, including software and data platforms designed for researchers, therapy developers, and clinicians. The firm also focuses on solutions that assist patients and caregivers in managing neurological and psychiatric conditions. Additionally, Nexus NeuroTech Ventures invests in sensors, monitoring systems, and diagnostic technologies that help detect brain disorder risks and treatment responses.
Medical devices that modulate or treat brain disorders are another critical area of investment for the firm. They also support therapy enabling technologies for drug and biologic delivery, as well as research tools that facilitate scientific research and clinical workflows. Nexus NeuroTech Ventures makes investments across seed and Series A to C stages, and it actively supports earlier-stage programs through its Nexus NeuroTech Incubator Program, which is designed to nurture innovative ideas in brain health.
Nexus NeuroTech Ventures has begun to establish its portfolio with a focus on innovative companies in the brain health sector. Notable companies in their portfolio include:
Jordi Parramon, PhD: General Partner & Co-Founder. Jordi has a background in neuroscience and venture capital, having previously worked at leading firms in the healthcare sector. He holds a PhD in Neuroscience and has a strong track record in identifying promising technologies in brain health.
William J. Marks, Jr., MD, MS-HCM: General Partner & Co-Founder. William is a physician with expertise in healthcare management and has led numerous investments in biotech and medical devices. He holds an MD and a Master’s in Healthcare Management.
Jon Lundt, PhD: Principal. Jon has a background in biomedical engineering and has experience in product development for medical technologies. He holds a PhD in Biomedical Engineering.
John Propst, PhD, MBA: Principal. John combines his expertise in neuroscience with business acumen, having worked in both research and venture capital. He holds a PhD in Neuroscience and an MBA.
Edward Ruppel III, MSE: Senior Associate. Edward has a background in engineering and has been involved in various healthcare startups, focusing on technology commercialization. He holds a Master’s in Engineering.
To pitch Nexus NeuroTech Ventures, founders should send an email to info@nexusneurotech.com. The pitch deck should include a comprehensive overview of the technology, market analysis, and the team’s qualifications. It is important to clearly outline the problem being addressed and how the proposed solution stands out in the market.
Founders can expect a response within a few weeks, although timelines may vary based on the volume of inquiries. Warm introductions are beneficial but not mandatory. The firm encourages direct outreach from passionate founders with innovative ideas in brain health.
Nexus NeuroTech Ventures operates the Nexus NeuroTech Incubator Program, which is designed to support early-stage companies developing technologies for brain disorders. This program provides resources, mentorship, and networking opportunities to help startups refine their products and business models. Eligible companies are those focused on innovative solutions in the healthcare and biotech sectors, particularly those addressing neurodegenerative, neuropsychiatric, and neurodevelopmental disorders.
To apply for the Nexus NeuroTech Incubator Program, interested founders should reach out via email to info@nexusneurotech.com, providing details about their technology and business plan.
Nexus NeuroTech Ventures has been actively building its portfolio since its founding in 2023. The firm has made notable investments in companies such as Ampa Health and Cala Health, which are focused on innovative solutions for brain disorders. As of now, there have been no public announcements regarding exits or additional fund raises.
The firm has not published any recent blog posts or updates, indicating a concentrated effort on portfolio development rather than external communications. This focus suggests that Nexus NeuroTech Ventures is prioritizing the growth and success of its current investments.
What are Nexus NeuroTech Ventures' investment criteria?
Nexus NeuroTech Ventures focuses on technologies and services that address brain disorders, including neurodegenerative, neuropsychiatric, and neurodevelopmental conditions. They invest in companies developing software platforms, medical devices, and therapy enabling technologies.
How can I apply or pitch to Nexus NeuroTech Ventures?
Founders can pitch their ideas by sending an email to info@nexusneurotech.com. It is advisable to include a detailed overview of the technology, market potential, and team background in the pitch.
What makes Nexus NeuroTech Ventures different from other VC firms?
Nexus NeuroTech Ventures specializes in brain health technologies, focusing on a specific sector that addresses critical health challenges. Their dedicated Nexus NeuroTech Incubator Program supports early-stage innovations, providing additional resources and mentorship.
What is the geographic scope of Nexus NeuroTech Ventures?
The firm primarily invests in North America, targeting companies that are developing solutions for brain disorders within this region.
What is the fund size or check size for investments?
While specific fund size details have not been disclosed, Nexus NeuroTech Ventures makes investments across seed and Series A to C stages, indicating a flexible check size that aligns with the needs of early-stage companies.
What kind of post-investment involvement can founders expect?
Nexus NeuroTech Ventures is committed to supporting its portfolio companies through mentorship, access to resources, and potential follow-on investments, particularly through their Nexus NeuroTech Incubator Program.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.